Marvel Biosciences announced that MB-204, their lead drug candidate, demonstrated significant effectiveness in reversing autism-related behaviors in a preclinical Shank3 mouse model study. The high dose of MB-204 normalized multiple behavioral abnormalities better than its parent drug, Istradefylline. These promising results support moving MB-204 into Phase 1 clinical trials, marking a key step toward a potential new treatment for autism spectrum disorder and related neurodevelopmental conditions. The company is also expanding its investor outreach as it prepares for human testing.
Marvel Biosciences' MB-204 drug candidate is advancing toward Phase 1 clinical trials following promising preclinical results. For readers following the health sector, here is Pluang's market snapshot as of Nov 10, 2026 17:11 WIB: out of 150 priced US health stocks, 70 rose and 65 fell. Notable movers include BBIO at USD 76.71 with 98% sell orders, LFST at USD 14.81 up 1.44%, and ENVB at USD 1.46 up 1.39%.
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
ESET Research uncovered a sophisticated cyberespionage tool named Cereal, used by the Russia-aligned Turla group to spy on emails within Microsoft Exchange servers of governmental organizations in Kazakhstan and Romania. The tool stealthily collects ...
The global paracetamol market is projected to grow from $12.05 billion in 2026 to $15.39 billion by 2032, with a CAGR of 4.12%. Growth is driven by increasing demand for pain and fever management, expanded access to over-the-counter medicines, and in...
Registration is now open for Brand Licensing Expo 2027, scheduled for May 25-27 at Mandalay Bay, Las Vegas. The event, rebranded from Licensing Expo, features over 265 confirmed exhibitors including major brands like Amazon MGM Studios, Coca-Cola, an...
Trogenix, a clinical-stage precision oncology company, has appointed John Young as Chair and Josh Murray as Non-Executive Director to support its global strategy, commercial growth, and US expansion. John Young brings over 35 years of pharmaceutical ...
